TriSalus Life Sciences, Inc.
$4.6
▲
1.44%
2026-04-21 09:50:01
trisaluslifesci.com
NGM: TLSI
Explore TriSalus Life Sciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$285.58 M
Current Price
$4.6
52W High / Low
$7.95 / $3.42
Stock P/E
—
Book Value
$-0.68
Dividend Yield
—
ROCE
-113.07%
ROE
131.29%
Face Value
—
EPS
$-1.84
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
102
Beta
0.54
Debt / Equity
-1.02
Current Ratio
2.8
Quick Ratio
2.54
Forward P/E
-16.88
Price / Sales
5.74
Enterprise Value
$272.72 M
EV / EBITDA
-10.36
EV / Revenue
6.04
Rating
None
Target Price
$9.2
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Boston Scientific Corporation | $65.03 | 33.52 | $96.13 B | 0% | 10.39% | 12.45% | $109.5 / $60.59 | $16.34 |
| 2. | Myomo, Inc. | $0.9 | — | $34.65 M | — | -47.54% | -86.24% | $4.99 / $0.6 | $0.3 |
| 3. | Sight Sciences, Inc. | $4.36 | — | $220.88 M | — | -35.58% | -50.74% | $9.24 / $2.4 | $1.2 |
| 4. | Smith & Nephew plc | $32.71 | 22.84 | $14.01 B | 2.29% | 9.67% | 11.84% | $1,441.5 / $960.8 | $6.22 |
| 5. | Picard Medical, Inc. | $0.9 | — | $69.69 M | — | -344.07% | 270.74% | $13.68 / $0.9 | $0.05 |
| 6. | Bio-Rad Laboratories, Inc. | NOT FOUND | — | — | — | 2.17% | 10.84% | $343.12 / $211.43 | $276.16 |
| 7. | Lifeward Ltd. | $7.52 | — | $11.49 M | — | -155.52% | -1.46% | $18.6 / $4.14 | $5.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 13.21 M | 11.57 M | 11.21 M | 9.17 M | 8.26 M | — |
| Operating Profit | -3.27 M | -9.01 M | -7.33 M | -7.33 M | -7.58 M | — |
| Net Profit | -9.75 M | -10.81 M | -8.29 M | -10.38 M | -10.11 M | — |
| EPS in Rs | -0.16 | -0.18 | -0.13 | -0.17 | -0.16 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 45.15 M | 29.43 M | 18.51 M | 12.4 M |
| Operating Profit | -26.95 M | -36.16 M | -54.48 M | -36.44 M |
| Net Profit | -39.23 M | -30.05 M | -59.36 M | -47.19 M |
| EPS in Rs | -0.64 | -0.49 | -0.97 | -0.77 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 35.33 M | 23.97 M | 24.6 M | 22 M |
| Total Liabilities | 69.19 M | 49.87 M | 51.66 M | 198.32 M |
| Equity | -33.86 M | -25.89 M | -27.07 M | -176.33 M |
| Current Assets | 32.24 M | 20.67 M | 20.86 M | 17.21 M |
| Current Liabilities | 11.5 M | 10.23 M | 14.69 M | 32.36 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -18.01 M | -40.84 M | -50.58 M | -32.31 M |
| Investing CF | -0.84 M | -0.34 M | -1.59 M | -1.79 M |
| Financing CF | 30.76 M | 37.94 M | 54.63 M | 13.46 M |
| Free CF | -18.93 M | -41.19 M | -51.17 M | -33.1 M |
| Capex | -0.92 M | -0.34 M | -0.59 M | -0.79 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 58.99% | 49.31% | — | — |
| Earnings Growth % | 49.39% | -25.8% | — | — |
| Profit Margin % | -102.09% | -320.69% | -380.6% | — |
| Operating Margin % | -122.88% | -294.28% | -293.91% | — |
| Gross Margin % | 86.06% | 85.93% | 81.79% | — |
| EBITDA Margin % | -89.04% | -316.86% | -377.31% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.